Peer Reviewed Publications

  • Home/
  • Peer Reviewed Publications

2022

January

  1. Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda.

Joussef-Piña S, Nankya I, Nalukwago S, Baseke J, Rwambuya S, Winner D, Kyeyune F,

Chervenak K, Thiel B, Asaad R, Dobrowolski C, Luttge B, Lawley B, Kityo CM,

Boom    WH, Karn J, Quiñones-Mateu ME. 15 Jan 2022, Reduced and highly diverse

peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1

strains in Uganda. Retro virology 19, 1 (2022). Doi: 10.1186/s12977-022-00587-3.

  1. Sex modifies the association between HIV and coronary artery disease among older adults in Uganda. Longenecker CT, Bogorodskaya M, Margevicius S, Nazzinda R, Bittencourt MS, Erem G, Nalukwago S, Huaman MA, Ghoshhajra BB, Siedner MJ, Juchnowski SM, Zidar DA, McComsey GA, Kityo C. Published 07 January 2022 Journal of the International AIDs Society Volume 25 issue 1 (1): Article ID: JIA225868. https://doi.org/10.1002/jia2.25868

      https://onlinelibrary.wiley.com/doi/10.1002/jia2.25868

February

  1. Brief Report: No Differences Between Lopinavir/Ritonavir and Non-nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy on Clearance of Plasmodium Falciparum Subclinical Parasitemia in Adults Living with HIV Starting Treatment (A5297). Douglas Shaffer1, Johnstone Kumwenda 2, Huichao Chen 3, Victor Akelo 4, Francis Angira 4, Josphat Kosgei 5, Ronald Tonui 6, Francis Ssali 7, Ashley McKhann 3, Evelyn Hogg 8, V Ann Stewart 9, Sean C Murphy 10, Robert Coombs 11 12, Robert Schooley 13, A5297 Team. Journal of Acquired Immune Deficiency Syndromes(JAIDS): February 1, 2022 – Volume 89 – Issue 2 – p 178-182 PMID: 34693933  DOI: 10.1097/QAI.0000000000002839 https://journals.lww.com/jaids/Abstract/2022/02010/Brief_Report__No_Differences_Between.10.aspx.
  2. Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1. Lombaard J, Ssali F, Thanyawee P, Fourie J, Vanveggel S, Linthicum C, Van Eygen V, Van Solingen-Ristea R. ASM journals/Antimicrobial Agents and Chemotherapy /volume 66,No.2. 2022 Feb 15;66(2): e0091621. doi: 10.1128/AAC.00916-21. PMID: 
  1. Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial. Rebecca1, Anna Turkova 2, Cecilia L Moore 2, Alasdair Bamford 2 3 4, Moherndran Archary, 5 6, Linda N Barlow-Mosha 7, Mark F Cotton 8, Tim R Cressey 9 10, Elizabeth Kaudha 11, Abbas Lugemwa 12, Hermione Lyall 13, Hilda A Mujuru 14, Veronica Mulenga 15, Victor Musiime 11 16, Pablo Rojo 17, Gareth Tudor-Williams 18, Steven B Welch 19, Diana M Gibb 2, Deborah Ford # 2, Ian R White # 2, and the ODYSSEY Trial Team BMC Medical Research Methodology 2022 Feb 20;22(1):49 volume 22, Article number: 49 (2022) doi: 10.1186/s12874-022-01539-3

 

  1. Children living with HIV: a narrative review of recent advances in pediatric HIV research and their implications for clinical practice. Damalie Nalwanga1, Victor Musiime 2  .Therapeutic advances in infectious diseases SAGE February 16, 2022 ;9:20499361221077544 .https://doi.org/10.1177/20499361221077544.

March

April

  1. Asymptomatic SARS-CoV-2 Infection is Common among ART-treated People with HIV.

Edgar T Overton 1, Isabelle R. Weir 2, Markella V. Zanni3, Stephanie Fischinger4, Rodger D. MacArthur5 , Judith A. Aberg6 , Kathleen V. Fitch3 , Michael Frank7 , Helmut Albrecht8 , Elliot Goodenough9 , Frank Rhame10 , Carl J. Fichtenbaum11, Gerald S. Bloomfield12, Carlos Malvestutto13, Sara McCallum3 , Pamela S. Douglas12, Galit Alter4 , Heather Ribaudo2 , Steven K. Grinspoon3. AIDS Journal of Acquired Immune Deficiency Syndromes: April 12, 2022 – Volume – Issue – 10.1097/QAI.0000000000003000 doi: 10.1097/QAI.0000000000003000)

 

https://journals.lww.com/jaids/Abstract/9900/Asymptomatic_SARS_CoV_2_Infection_is_Common_among.27.aspx

  1. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either Zidovudine or Tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, Multicentre, open-label, factorial, randomized, non-inferiority trial.

Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Asienzo J, Kaimal A, Mirembe G, Lugemwa A, Ategeka G, Borok M, Mugerwa H, Siika A, Odongpiny ELA, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team.The Lancet HIV. 2022 Apr 20: S2352-3018(22)00092-3.   Doi: 10.1016/S2352-3018(22)00092-3. Online ahead of print. PMID: 35460601 

  1. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.

Solomon SS, Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA, Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-Bagur J, Benson CA, Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M. The Lancet Gastroenterology and Hepatology. Articles volume 7, issue 4,P307-317, April 01,2022. https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00397-6/fulltext.    DOI:https://doi.org/10.1016/S2468-1253(21)00397-6

 

  1. Antiretroviral initiation at ≥800 CD4+ cells/ mm 3 associated with lower HIV reservoir size.Rasmussen TA, Ahuja SK, Kuwanda L, Vjecha MJ, Hudson F, Lal L, Rhodes A, Chang J, Palmer S, Auberson-Munderi P, Mugerwa H, Wood R, Badal-Faesen S, Pillay S, Mngqibisa R, LaRosa A, Hildago J, Petoumenos K, Chiu C, Lutaakome J, Kitonsa J, Kabaswaga E, Pala P, Ganoza C, Fisher K, Chang C, Lewin SR, Wright EJ.Clinical Infectious Diseases. 2022 Apr 9:ciac249. doi: https://doi.org/10.1093/cid/ciac249. Online ahead of print. PMID: 35396591

May

  1. Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multi-country longitudinal cohort analysis.

Inzaule SC, Kroeze S, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Steegen K, Nankya I, Boender TS, Ondoa P, Sigaloff KCE, de Wit TFR, Hamers RL.AIDS. 2022 May 24. Doi: 10.1097/QAD.0000000000003270. Online ahead of print. PMID: 35608116

  1. Clinical Outcomes, Echocardiographic Findings, and Care Quality Metrics for People Living With Human Immunodeficiency Virus (HIV) and Rheumatic Heart Disease in Uganda.

Chang AY, Rwebembera J, Bendavid E, Okello E, Barry M, Beaton AZ, Haeffele C, Webel AR, Kityo C, Longenecker CT. Clinical Infectious Diseases, Volume 74, Issue 9, 1 May 2022, Pages 1543–1548, https://doi.org/10.1093/cid/ciab681

  1. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalized with COVID-19 (TICO): a randomised controlled trial.ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Lancet Infectious Diseases. 2022 May;22(5): Volume 22, Issue 5,p622-635. doi: 10.1016/S1473-3099(21)00751-9.
  1. Ambient air pollution is associated with vascular disease in Ugandan HIV-positive adolescents. Toe S, Nagy M, Albar Z, Yu J, Sattar A, Nazzinda R, Musiime V, Etajak S, Walyawula F, McComsey GA, Atuyambe LM, Dirajlal-Fargo S.May 1,2022-Volume 36-Issue 6-p863-870. doi: 10.1097/QAD.0000000000003186.

https://journals.lww.com/aidsonline/Abstract/2022/05010/Ambient_air_pollution_is_associated_with_vascular.12.aspx

 

  1. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.Waalewijn H, Chan MK, Bollen PDJ, Mujuru HA, Makumbi S, Kekitiinwa AR, Kaudha E, Sarfati T, Musoro G, Nanduudu A, Lugemwa A, Amuge P, Moore CL, Rojo P, Giaquinto C, Colbers A, Gibb DM, Ford D, Turkova A, Burger DM; ODYSSEY Trial Team. The Lancet HIV.Volume 9, Issue 5, e341-e352, May 01,2022. doi: 10.1016/S2352-3018(21)00292-7.

June

2021

January

  1. Failure is not an option: Barriers to HIV treatment adherence in Kampala, Uganda Bruser G, Katasi R, Zhang LZ, Namasinga M, Arts E, Kityo C, Luginaah I. Health Place. 2021 Jan;67:102481. doi: 10.1016/j.healthplace.2020.102481. Epub 2020 Dec 1. PMID: 33276263.
  2. The Association of Kidney Disease with Abnormal Cardiac Structure and Function among Ugandans with HIV InfectionMatthew Peters, SeungheeMargevicius, Cissy Kityo, Grace Mirembe, Jonathan Buggey, Ellen Brinza, Mark Schluchter, Chun-Ho Yun, Chung-Lieh Hung, Grace A McComsey, Chris T Longenecker. JAcquir Immune DeficSyndr. 2021 Jan 1;86(1):104-109 doi: 10.1097/QAI.0000000000002529.PMID: 33044321
  3. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.Dunn D, Price H, Vudriko T, Kityo C, Musoro G, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R; DART Virology Group. JAcquir Immune DeficSyndr. 2021 Jan 1;86(1):98-103. doi: 10.1097/QAI.0000000000002517.PMID: 33306565
  4. ODYSSEY clinical trial design: a randomized global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravirdosing.Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Saϊdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D; ODYSSEY Trial Team. BMC Infect Dis. 2021 Jan 4;21(1):5. doi: 10.1186/s12879-020-05672-6.PMID: 33446115 Free PMC article. Clinical Trial.
  5. Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala Uganda.Nabukeera S, Kagaayi J, Makumbi FE, Mugerwa H, MatovuJKB. PLoS One. 2021 Jan 27;16(1): e0246140. doi: 10.1371/journal.pone.0246140. eCollection 2021.PMID: 33503074 Free PMC article.
  6. Deep Gene Sequence Cluster Analyses of Multi-Virus-Infected Mucosal Tissue Reveal Enhanced Transmission of Acute HIV-1.Klein K, Nankya I, Nickel G, Ratcliff AN, Meadows AAJ, Hathaway N, Bailey JA, Stieh DJ, Cheeseman HM, Carias AM, Lobritz MA, Mann JFS, Gao Y, Hope TJ, Shattock RJ, Arts EJ.Klein K, et al. 2021 Jan 13;95(3): e01737-20. doi: 10.1128/JVI.01737-20. Print 2021 Jan 13.J Virol. 2021.PMID: 33177204Free article.

  7. Aminimal monitoring approach for the treatment of hepatitis C virus infection (ACTG
    A5360 [MINMON]): a phase 4, open-label, single-arm trial.    Solomon SS,
    Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, Brates I, Scello
    C, Son A, Avihingsanon A, Linas B, Anthony D, Nunes EP, Kliemann DA,
    Supparatpinyo K, Kityo C, Tebas P, Bennet JA, Santana-Bagur J,
    Benson CA,Van Schalkwyk M, Cheinquer N, Naggie S, Wyles D, Sulkowski M.    .A minimal monitoring approach for the treatment of hepatitis.
    The Lancet Gastroenterology&Hepatology 10 Jan 2022 1253(21)00397-6.  DOI:10.1016/S2468-1253(21)00397-6. Online
    ahead of print. PMID: 35026142.       https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00397-6/fulltext.

  8. Reduced and highly diverse peripheral HIV-1 reservoir in
    virally suppressed patients infected with non-B HIV-1 strains in Uganda.

    Joussef-Piña S, Nankya I, Nalukwago S, Baseke J, Rwambuya S, Winner D, Kyeyune F,

    Chervenak K, Thiel B, Asaad R, Dobrowolski C, Luttge B, Lawley B, Kityo CM, Boom    WH, Karn J, Quiñones-Mateu ME. 15 Jan 2022, Reduced

    and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda. Retro virology 19, 1 (2022).                                   https://doi.org/10.1186/s12977-022-   00587-3

  9. Sex modifies the association
    between HIV and coronary artery disease among older adults in Uganda.     Longenecker CT, Bogorodskaya M, Margevicius S, Nazzinda R,
    Bittencourt MS, Erem G, Nalukwago S, Huaman MA, Ghoshhajra BB, Siedner MJ,
    Juchnowski SM, Zidar DA, McComsey GA, Kityo C.     Published 07
    January 2022     Journal of the International AIDs Society  Volume 25
    issue 1 (1):     Article ID:
    JIA225868    . https://doi.org/10.1002/jia2.25868     https://onlinelibrary.wiley.com/doi/10.1002/jia2.25868

February

  1. Urine LAM Testing in Advanced HIV Positive Adults in a Trial of Empiric TB Therapy. Matoga MM, Bisson GP, Gupta A, Miyahara S, Sun X, Fry C, Manabe YC, Kumwenda J, Cecilia K, Nyirenda M, Ngongondo M, Mbewe A, Lagat D, Wallis C, Mugerwa H, HosseinipourMC.Matoga MM, et al. Clin Infect Dis. 2021 Feb 26:ciab179. doi: 10.1093/cid/ciab179. Online ahead of print. Clin Infect Dis. 2021.PMID: 33638976                         
  2. Brief Report: No Differences Between
    Lopinavir/Ritonavir and Nonnucleoside Reverse Transcriptase Inhibitor-Based
    Antiretroviral Therapy on Clearance of Plasmodium Falciparum Subclinical
    Parasitemia in Adults Living with HIV Starting Treatment (A5297).    Douglas Shaffer 1, Johnstone Kumwenda 2, Huichao Chen 3, Victor Akelo 4, Francis Angira 4, Josphat Kosgei 5, Ronald Tonui 6, Francis Ssali 7, Ashley McKhann 3, Evelyn Hogg 8, V Ann Stewart 9, Sean C Murphy 10, Robert Coombs 11 12, Robert Schooley 13, A5297 Team. Journal of Acquired Immune Deficiency Syndromes(JAIDS): February 1, 2022 –
    Volume 89 – Issue 2 – p 178-182     PMID: 34693933 
    DOI: 10.1097/QAI.0000000000002839

  3. https://journals.lww.com/jaids/Abstract/2022/02010/Brief_Report__No_Differences_Between.10.aspx

  4. Ambient air pollution is associated with vascular disease
    in Ugandan HIV positive adolescents.    Toe S, Nagy M, Albar Z, Yu J, Sattar A, Masinda R, Musiime
    V    , Etajak S, Walyawula F, Mccomsey GA, Atuyambe LM, Dirajlal-Fargo S.    AIDS journal. 2022 Feb
    8. doi: 10.1097/QAD.0000000000003186. Online ahead of print.     PMID: 35131961   https://journals.lww.com/aidsonline/Abstract/9000/Ambient_air_pollution_is_associated_with_vascular.96226.aspx

  5. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled TriaL. ACTIV-3/TICO Bamlanivimab Study Group, Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Goodman AL, Chang W, Dewar RL, Gerry NP, Higgs ES, Highbarger H, Murray DD, Murray TA, Natarajan V, Paredes R, Parmar MKB, Phillips AN, Reilly C, Rupert AW, Sharma S, Shaw-Saliba K, Sherman BT, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Davey VJ, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD.Annals of Intern Med. 2022 Feb;175(2):234-243. doi: 10.7326/M21-3507. Epub 2021 Dec 21. PMID: 34928698

  6. Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1. Lombaard J, Ssali F, Thanyawee P, Fourie J, Vanveggel S, Linthicum C, Van Eygen V, Van    Solingen-Ristea R. ASM journals/Antimicrobial Agents and Chemotherapy /volume 66,No.2. 2022 Feb 15;66(2): e0091621. doi: 10.1128/AAC.00916-21. PMID: 3487108.

  7.  

    Borrowing information across patient subgroups in clinical trials, with application to a
    paediatric trial.     Rebecca 1, Anna Turkova 2, Cecilia L Moore 2, Alasdair
    Bamford     2 3 4, Moherndran Archary, 5 6, Linda N Barlow-Mosha 7, Mark F Cotton 8, Tim
    R Cressey     9 10, Elizabeth Kaudha 11, Abbas Lugemwa 12, Hermione Lyall 13, Hilda A Mujuru 14, Veronica Mulenga 15, Victor Musiime 11 16, Pablo Rojo 17, Gareth Tudor-Williams 18, Steven B Welch 19, Diana M Gibb 2, Deborah Ford # 2, Ian R White # 2, and
    the ODYSSEY Trial Team     BMC Medical Research Methodology 2022 Feb 20;22(1):49 volume 22,
    Article number: 49 (2022)     doi:
    10.1186/s12874-022-01539-3

  8. Children living with HIV: a narrative review of recent advances in pediatric HIV
    research and their implications for clinical practice.     Damalie
    Nalwanga     1, Victor
    Musiime     2  .Therapeutic advances in infectious diseases SAGE journals.
    February 16, 2022 ;9:20499361221077544 .    https://doi.org/10.1177/20499361221077544.

March

  1. Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status. Pett SL, Spyer M, Haddow LJ, Nhema R, Benjamin LA, Najjuka G, Bilima S, Daud I, Musoro G, Kitabalwa J, Selemani G, Kandie S, Cornelius KM, Katemba C, Berkley JA, Hassan AS, Kityo C, Hakim J, Heyderman RS, Gibb DM, Walker AS; REALITY trial team. AIDS. 2021 Mar 15;35(4):585-594. doi: 10.1097/QAD.0000000000002781.PMID: 33306556
  2. Monocyte activation in persons living with HIV and tuberculosis coinfection.Huaman MA, Juchnowski SM, Zidar DA, Kityo CM, Nalukwago S, Nazzinda R, Fichtenbaum CJ, Longenecker CT. 2021 Mar 1;35(3):447-452. doi: 10.1097/QAD.0000000000002766.PMID: 33252496

April

  1. Lipidome association with vascular disease and inflammation in HIV+ Ugandan children. Dirajlal-Fargo S, Sattar A, Yu J, Albar Z, Chaves FC, Riedl K, Kityo C, Bowman E, Mccomsey GA, Funderburg N. 2021 Apr 19. doi: 10.1097/QAD.0000000000002923. Epub ahead of print. PMID: 33878042.
  2. Facilitated transition in HIV drug trial closure: a conceptual model for HIV post-trial care. Nalubega S, Cox K, Mugerwa H, Evans C. PLoS One. 2021 Apr 29;16(4): e0250698. doi: 10.1371/journal.pone.0250698. PMID: 33914783; PMCID: PMC8084151.
  3. Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda. Musana H, Ssensamba JT, Nakafeero M, Mugerwa H, Kiweewa FM, Serwadda D, Ssali F. AIDS Res Ther. 2021 Apr 21;18(1):17. doi: 10.1186/s12981-021-00338-y. PMID: 33882938; PMCID: PMC8059285.
  4. Neurocognitive function among HIV-infected children on protease inhibitor -based versus non-protease inhibitor based antiretroviral therapy in Uganda: a pilot study.Nalwanga D, Musiime V, Bangirana P, Nishiguchi EP, Kiggwe A, Ssesanga T, Ssenkusu JM, Musoke P, Cusick SE. BMC Pediatric. 2021 Apr 26;21(1):198. doi: 10.1186/s12887-021-02676-2.PMID: 33902506
  5. Mortality among children under five years admitted for routine care of severe acute malnutrition: a prospective cohort study from Kampala, Uganda.Nalwanga D, Musiime V, Kizito S, Kiggundu JB, Batte A, Musoke P, Tumwine JK. BMC Pediatric. 2020 Apr 24;20(1):182. doi: 10.1186/s12887-020-02094-w.PMID: 32331517

May

  1. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium.. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. PMID: 33951360.

June

  1. Sex, HIV Status, and Measures of Cardiac Stress and Fibrosis in Uganda. Kipke J, Margevicius S, Kityo C, Mirembe G, Buggey J, Yun CH, Hung CL, McComsey GA, Longenecker CT. J Am Heart Assoc. 2021 Jun;10(11): e018767. doi: 10.1161/JAHA.120.018767. Epub 2021 May 15. PMID: 33998251.
  2. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda.Muttamba W, Lusiba J, Namakula LO, Byakika-Kibwika P, Ssali F, Ddungu H, Mugenyi L, Kiwanuka N, Sekibira R, Kityo C, Keyune D, Acana S, Musinguzi A, Masasi A, Byamugisha J, Mpanju D, Musoki WJ, Tukamuhebwa HA, Nakwagala F, Bagaya BS, Kayongo A, Kimuli I, Nantanda R, Katagira W, Buregyeya E, Byanyima R, Byarugaba B, Siddharthan T, Mwebesa H, Charles O, Joloba ML, Bazeyo W, Kirenga B.. PLoS One. 2021 Jun 17;16(6): e0252306. doi: 10.1371/journal.pone.0252306. PMID: 34138909; PMCID: PMC8211202.

July

  1. Ethical and practical considerations in HIV drug trial closure: perspectives of research staff in Uganda: SyliviaNalubega, Karen Cox, Henry Mugerwa, Catrins Evans, Research Ethics 2021, Vol. 17(4) 423–434 DOI: 10.1177/17470161211030971 
  2. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Kaimal A, Mirembe G, Tukamushabe P, Ategeka G, Hakim J, Mugerwa H, Siika A, Asienzo J, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Engl J Med. 2021 Jul 22;385(4):330-341. doi: 10.1056/NEJMoa2101609.PMID: 34289276 Clinical Trial. 
  3. Translocated microbiome composition determines immunological outcome in treated HIV infection.Nganou-Makamdop K, Talla A, Sharma AA, Darko S, Ransier A, Laboune F, Chipman JG, Beilman GJ, Hoskuldsson T, Fourati S, Schmidt TE, Arumugam S, Lima NS, Moon D, Callisto S, Schoephoerster J, Tomalka J, Mugyenyi P, Ssali F, Muloma P, Ssengendo P, Leda AR, Cheu RK, Flynn JK, Morou A, Brunet-Ratnasingham E, Rodriguez B, Lederman MM, Kaufmann DE, Klatt NR, Kityo C, Brenchley JM, Schacker TW, Sekaly RP, DouekDC. 2021 Jul 22;184(15):3899-3914.e16. doi: 10.1016/j.cell.2021.05.023. Epub 2021 Jul 7. PMID: 34237254 
  4. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicenter, phase 2/3 trial. Gaur AH, Cotton MF, Rodriguez CA, McGrath EJ, Helström E, Liberty A, Natukunda E, Kosalaraksa P, Chokephaibulkit K, Maxwell H, Wong P, Porter D, Majeed S, Yue MS, Graham H, Martin H, Brainard DM, Pikora C.. Lancet Child Adolesc Health. 2021 Sep;5(9):642-651. doi: 10.1016/S2352-4642(21)00165-6. Epub 2021 Jul 22. PMID: 34302760.

August

  1. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda.Kirenga B, Byakika-Kibwika P, Muttamba W, Kayongo A, Loryndah NO, Mugenyi L, Kiwanuka N, Lusiba J, Atukunda A, Mugume R, Ssali F, Ddungu H, Katagira W, Sekibira R, Kityo C, Kyeyune D, Acana S, Aanyu-Tukamuhebwa H, Kabweru W, Nakwagala F, Bagaya BS, Kimuli I, Nantanda R, Buregyeya E, Byarugaba B, Olaro C, Mwebesa H, Joloba ML, Siddharthan T, Bazeyo W. BMJ Open Respir Res. 2021 Aug;8(1):e001017. doi: 10.1136/bmjresp-2021-001017.PMID: 34376401
  2. Plasma Inflammatory Biomarkers Predict CD4+ T-cell Recovery and Viral Rebound in HIV-1 Infected Africans on Suppressive Antiretroviral Therapy.Kroeze S, Rossouw TM, Steel HC, Wit FW, Kityo CM, Siwale M, Akanmu S, Mandaliya K, De Jager M, Ondoa P, Reiss P, Rinke De Wit TF, Kootstra NA, Hamers RL. J Infect Dis. 2021 Aug 16;224(4):673-678. doi: 10.1093/infdis/jiaa787.PMID: 33373447.
  3. Clinical Outcomes, Echocardiographic Findings, and Care Quality Metrics for People Living with HIV and Rheumatic Heart Disease in Uganda.Chang AY, Rwebembera J, Bendavid E, Okello E, Barry M, Beaton AZ, Haeffele C, Webel AR, Kityo C, Longenecker CT. Clin Infect Dis. 2021 Aug 12:ciab681. doi: 10.1093/cid/ciab681. Online ahead of print. PMID: 34382644
  4. Efficacy of cipargamin (KAE609) in a randomized, Phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria.Schmitt EK, Ndayisaba G, Yeka A, Asante KP, Grobusch MP, Karita E, Mugerwa H, Asiimwe S, Oduro A, Fofana B, Doumbia S, Su G, Csermak Renner K, Venishetty VK, Sayyed S, Straimer J, Demin I, Barsainya S, Boulton C, Gandhi P. Clin Infect Dis. 2021 Aug 19:ciab716. doi: 10.1093/cid/ciab716. Online ahead of print. PMID: 34410358
  5. Urine Lipoarabinomannan Testing in Adults With Advanced Human Immunodeficiency Virus in a Trial of Empiric Tuberculosis Therapy.Matoga MM, Bisson GP, Gupta A, Miyahara S, Sun X, Fry C, Manabe YC, Kumwenda J, Cecilia K, Nyirenda M, Ngongondo M, Mbewe A, Lagat D, Wallis C, Mugerwa H, HosseinipourMC. Clin Infect Dis. 2021 Aug 16;73(4):e870-e877. doi: 10.1093/cid/ciab179.PMID: 34398958 
  6. The impact of viraemia on inflammatory biomarkers and CD4+ cell subpopulations in HIV-infected children in sub-Saharan Africa.Prendergast AJ, Szubert AJ, Pimundu G, Berejena C, Pala P, Shonhai A, Hunter P, Arrigoni FIF, Musiime V, Bwakura-Dangarembizi M, Musoke P, Poulsom H, Kihembo M, Munderi P, Gibb DM, Spyer MJ, Walker AS, Klein N; the ARROW Trial Team. AIDS. 2021 Aug 1;35(10):1537-1548. doi: 10.1097/QAD.0000000000002916.PMID: 34270487 

September

  1. Diagnostic accuracy of the Cepheid 3-gene host response fingerstick blood test in a prospective, multi-site study: interim results. Sutherland JS, van der Spuy G, Gindeh A, Thuong NT, Namuganga AR, Owolabi O, Mayanja-Kizza H, Nsereko M, Thwaites G, Winter J, Dockrell HM, Scriba TJ, Geluk A, Corstjens P, Stanley K, Richardson T, Shaw JA, Smith B, Malherbe ST, Walzl G; TrENDx-TB consortium. Clin Infect Dis. 2021 Sep 22:ciab839. doi: 10.1093/cid/ciab839. Online ahead of print.PMID: 34550342
  2. Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). Adair JE, Androski L, Bayigga L, Bazira D, Brandon E, Dee L, Deeks S, Draz M, Dubé K, Dybul M, Gurkan U, Harlow E, Kityo C, Louella M, Malik P, Mathews V, McKemey A, Mugerwa H, Muyanja D, Olayiwola O, Orentas RJ, Popovski A, Sheehy J, Ssali F, Nsubuga MS, Tisdale JF, Verhoeyen E, DropulićB. 2021 Sep 8. doi: 10.1038/s41434-021-00284-4. Online ahead of print.PMID: 34493840

October

  1. High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations. Ndashimye E, Li Y, Reyes PS, Avino M, Olabode AS, Kityo CM, Kyeyune F, Nankya I, Quiñones-Mateu ME, Barr SD, Arts EJ. JAntimicrob Chemother. 11;76(11):2965-2974. doi: 10.1093/jac/dkab276.PMID: 34453542
  2. A Sex-stratified Analysis of Monocyte Phenotypes Associated with HIV Infection in Uganda. Moises A. Huaman *, Manuel G. Feria, Cissy Kityo, Sophie Nalukwago, RashidahNazzinda, David A. Zidar, Markella V. Zanni, Mark J. Siedner, StevenK. Grinspoon, Chris T. Longenecker. Viruses2021, 13(11), 2135; https://doi.org/10.3390/v13112135
  3. Brief Report: No Differences Between Lopinavir/ritonavir and non-Nucleoside ReverseTranscriptase Inhibitor-based Antiretroviral Therapy on Clearance of Plasmodium falciparum Subclinical Parasitemia in Adults Living With HIV Starting Treatment (A5297). Shaffer D, Kumwenda J, Chen H, Akelo V, Angira F, Kosgei J, Tonui R, Ssali F, McKhannA, HoggE, Stewart VA, Murphy SC, Coombs R, Schooley R; A5297 Team. J Acquir Immune DeficSyndr. 2021 Oct 19. doi: 10.1097/QAI.0000000000002839.Online ahead of print.PMID: 34693933.

November

  1. A Simple Approach to Cure Hepatitis C Virus Infection: The Phase IV Multicounty ACTG 5360 (MINMON) Trial. Sunil Solomon, Sandra Wagner-Cardoso, Laura Smeaton, Leonard Sowah, ChanelleWimbish, Gregory Robbins, IrenaBrates, Christine Scello, Annie Son, AnchaleeAvihingsanon, Ben Linas,Donald Anthony, EstevãoPortelaNunes, BrenoRiegelSantos, KhuanchaiSupparatpinyo, Cissy Kityo, Penn Therapeutics Author, Jaclyn Ann Bennet, MB Jorge Santana-Bagur, Marije Van Schalkwyk, NelsonCheinquer, SusannaNaggie, DavidWyles, MarkSulkowski. The Lancet Gastroenterology & Hepatology. https://actgnetwork.org/2021/10/20/a5360 
  2. Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda.Huaman MA, De Cecco CN, Bittencourt MS, Ticona E, Kityo C, Ballena I,Nalukwago S, Nazzinda R, Ticona C, Azañero R, Zhang B, Farquhar C, Hawn TR, Sterling TR, Fichtenbaum CJ, Longenecker CT. Clin Infect Dis. 2021 Nov 2;73(9):e3384-e3390. doi: 10.1093/cid/ciaa1934.PMID: 33388766

December

  1. Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. Orkin C, Ajana F, Kityo C, Koenig E, Natukunda E, Gandhi-Patel B, Wang H, Liu Y, Wei X, White K, Makadzange T, Pikora C, McNicholl I, Collins SE, Brainard D, Chuck SK.J J Acquir Immune DeficSyndr. 2021 Dec 1;88(4):393-398. doi: 10.1097/QAI.0000000000002789.PMID: 34506342 Free PMC article. 
  2. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 Steven G. Deeks1 , Nancie Archin2 , Paula Cannon  3 , Simon Collins4, R. Brad Jones5 , Marein A. W. P. de Jong6, Olivier Lambotte7 , Rosanne Lamplough8, Thumbi Ndung’u9,10,11, Jeremy Sugarman  12, Caroline T. Tiemessen  13, LinosVandekerckhove  14, Sharon R. Lewin  15,16,17 and The International AIDS Society (IAS) Global Scientific Strategy working group* Nat Med. 2021 Dec;27(12):2085-2098. doi: 10.1038/s41591-021-01590-5. Epub 2021 Dec 1. PMID: 34848888
  3. Long-term safety, tolerability and antiviral activity of rilpivirine in antiretroviral-naïve adolescents living with HIV-1, aged 12 to less than 18 years: Week 240 findings of a phase 2, open-label study, PAINT. Lombaard J, Ssali F, Thanyawee P, Fourie J, Vanveggel S, Linthicum C, Van Eygen V, Van Solingen-RisteaR. Antimicrob Agents Chemother. 2021 Dec 6:AAC0091621. doi: 10.1128/AAC.00916-21. Online ahead of print.PMID: 34871089 
  4. ODYSSEY: Dolutegravir for First- and Second-Line HIV Treatment in Children" Turkova, Anna; White, Ellen; Henry Mujuru; Adeodata R. Kekitiinwa; Cissy M. Kityo; Violari; Abbas Lugemwa; Tim Cressey; ‘PhyllipaMusoke; Mark Cotton; thanyawee;obehuhuma; Steven Welch; Pauline Amuge; Elizabeth Kaudha; Linda barlow; Makumbi Shafic; Nastassja Ramsagar; ChaiwatNgampiyaskul; atwinelorna; Afaaf Abdullah; Victor Musiime; Dickson Bbuye; Grace Ahimbisibwe; SuwalaiChalermpantmetagul; Ali, Shabinah; Sarfati, Tatiana; Wynne, Ben; Shakeshaft, Clare; Angela,Colbers; Klein, Nigel; Sarah Bernays; yacine,saidi; Alexandra,coelho; TizianaGrossele; alexandra,Compagnucci; Carlo Giaquinto; Pablo,Rojoconejo; Ford, Deborah; Gibb, Diana. N Engl J Med. 2021 Dec 30;385(27):2531-2543. doi: 10.1056/NEJMoa2108793. 
  5. Sex modifies the association between HIV and coronary artery disease among older adults in Uganda" Longenecker, Chris; Bogorodskaya, Milana; Margevicius, Seunghee; Nazzinda, Rashidah; Bittencourt, Marcio; Erem, Geoffrey; Nalukwago, Sophie; Huaman, Moises; Ghoshhajra, Brian; Siedner, Mark; Juchnowski, Steven; Zidar, David; McComsey, Grace; Kityo, Cissy. Accepted in Journal of the International AIDS Society – Article ID: JIA225868

2020

  1. The Association of Kidney Disease with Abnormal Cardiac Structure and Function among Ugandans with HIV InfectionMatthew Peters, SeungheeMargevicius, Cissy Kityo, Grace Mirembe, Jonathan Buggey, Ellen Brinza, Mark Schluchter, Chun-Ho Yun, Chung-Lieh Hung, Grace A McComsey, Chris T Longenecker. JAcquir Immune Def 2021 Jan 1;86(1):104-109 PMID: 33044321.
  2. Micronutrients, Metabolic Complications and Inflammation in Ugandan Children with HIV.Dirajlal-Fargo S, Shan L, Sattar A, Kulkarni M, Bowman E, Funderburg N, Nazzinda R, Karungi C, Kityo C, Musiime V, Mccomsey GA. J PediatrGastroenterolNutr.2020 Jan 14.doi: 10.1097/MPG.0000000000002630. [Epub ahead of print]PMID:31939864
  3. HIV and pericardial fat are associated with abnormal cardiac structure and function among Ugandans.Buggey J, Yun L, Hung CL, Kityo C, Mirembe G, Erem G, Truong T, Ssinabulya I, Tang WHW, Hoit BD, McComsey GA, Longenecker CT.Heart. 2020 Jan; 106(2):147-153. doi: 10.1136/heartjnl-2019-315346 .PMID:31537637
  4. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.Ayitewala A, Kyeyune F, Ainembabazi P, Nabulime E, Kato CD, Nankya I.AIDS Res Ther. 2020 Jan 31;17(1):2. doi: 10.1186/s12981-020-0258-7.PMID: 32005262
  5. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-Infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings. David Dunn ,Huw Price, Tobias Vudrikoc, Cissy Kityo, Godfrey Musoro, James Hakim, Charles Gilks, PontianoKaleebu, Deenan Pillay, Richard Gilson, DART Virology Group.JAcquir Immune DeficSyndr. 2021. 2021 Jan 1;86(1):98-103. doi: 10.1097/QAI.0000000000002517 PMID: 33306565
  6. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda. Ayitewala A, Kyeyune F, Ainembabazi P, Nabulime E, Kato CD, Nankya I.AIDS Res Ther. 2020 Jan 31;17(1):2. doi: 10.1186/s12981-020-0258-7.PMID: 32005262
  7. Increased monocyte and T-cell activation in treated HIV+ ugandan children: associations with gut alteration and HIV factors.Dirajlal-Fargo S, Albar Z, Bowman E, Labbato D, Sattar A, Karungi C, Nazzinda R, Funderburg N, Kityo C, Musiime V, McComsey GA.AIDS. 2020 Feb 17. doi: 10.1097/QAD.0000000000002505. [Epub ahead of print]PMID:32073452
  8. The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa.Walker SM, Cox E, Revill P, Musiime V, Bwakura-Dangarembizi M, Mallewa J, Cheruiyot P, Maitland K, Ford N, Gibb DM, Walker AS, Soares M; REALITY trial team.JInt AIDS Soc. 2020 Mar;23(3):e25469. doi: 10.1002/jia2.25469.PMID: 32219991 Free PMC article.
  9. The cost‐effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in AfricaSimon M Walker, Edward Cox, Paul Revill, Victor Musiime, MutsaBwakura‐Dangarembizi, Jane Mallewa, Priscilla Cheruiyot, Kathryn Maitland, Nathan Ford, Diana M Gibb, A Sarah Walker, Marta Soares, the REALITY trial teamJInt AIDS Soc. 2020 Mar; 23(3): e25469. Published online 2020 Mar 27. doi: 10.1002/jia2.25469
  10. Altered Intestinal Permeability and Fungal Translocation in Ugandan Children With Human Immunodeficiency Virus.Dirajlal-Fargo S, El-Kamari V, Weiner L, Shan L, Sattar A, Kulkarni M, Funderburg N, Nazzinda R, Karungi C, Kityo C, Musiime V, McComseyGA.Clin Infect Dis. 2020 May 23;70(11):2413-2422. doi: 10.1093/cid/ciz561.PMID: 31260509 Free PMC article.
  11. Relationship between economic insecurity, inflammation, monocyte activation and intestinal integrity in children living with HIV in Uganda.Dirajlal-Fargo S, Albar Z, Sattar A, Kulkarni M, Bowman E, Funderburg N, Nazzinda R, Kityo C, Musiime V, McComsey GA. AIDS Care. 2020 Jun 15:1-6. doi: 10.1080/09540121.2020.1776822. Online ahead of print.PMID: 32539474
  12. Recombination Analysis of Near Full-Length HIV-1 Sequences and the Identification of a Potential New Circulating Recombinant Form from Rakai, Uganda.Capoferri AA, Lamers SL, Grabowski MK, Rose R, Wawer MJ, Serwadda D, Gray RH, Quinn TC, Kigozi G, Kagaayi J, Laeyendecker O; Rakai Health Sciences Program and the PANGEA Consortium.AIDS Res Hum Retroviruses. 2020 Jun; 36(6):467-474. doi: 10.1089/AID.2019.0150. Epub 2020 PMID: 31914792 
  13. Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapyRuth E. Farmer, Rhian Daniel, Deborah Ford, Adrian Cook, Victor Musiime, MutsaBwakura-Dangarembizi, Diana M. Gibb, Andrew J. Prendergast, A. Sarah Walker, on behalf of the ARROW trial teamPLoS One. 2020; 15(7): e0233877. Published online 2020 Jul 9. doi: 10.1371/journal.pone.0233877 
  14. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.Jacobs TG, Svensson EM, Musiime V, Rojo P, Dooley KE, McIlleron H, Aarnoutse RE, Burger DM, Turkova A, Colbers A; WHO Paediatric Antiretroviral Working Group. 2020 Aug 12:dkaa328. doi: 10.1093/jac/dkaa328. Online ahead of print.PMID: 32785712 
  15. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. Bollen PDJ, Moore CL, Mujuru HA, Makumbi S, Kekitiinwa AR, Kaudha E, Parker A, Musoro G, Nanduudu A, Lugemwa A, Amuge P, Hakim JG, Rojo P, Giaquinto C, Colbers A, Gibb DM, Ford D, Turkova A, Burger DM; ODYSSEY trial team. Lancet HIV. 2020 Aug; 7(8):e533-e544. doi: 10.1016/S2352-3018(20)30189-2. PMID: 32763217; PMCID: PMC7445428. 
  16. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. Inzaule SC, Bertagnolio S, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, Ondoa P, Sigaloff KCE, Rinke de Wit TF, Hamers RL. AIDS. 2020 Aug 1;34(10):1559-1566. doi: 10.1097/QAD.0000000000002588. PMID: 32675566. 
  17. Because we all have to grow up": supporting adolescents in Uganda to develop core competencies to transition towards managing their HIV more independently.Lanyon C, Seeley J, Namukwaya S, Musiime V, Paparini S, Nakyambadde H, Matama C, Turkova A, Bernays S.J Int AIDS Soc. 2020 Sep;23 Suppl 5(Suppl 5):e25552. doi: 10.1002/jia2.25552.PMID: 32869514 
  18. Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status,Sarah L Pett, Moira Spyer, Lewis J Haddow, Ruth Nhema, Laura A Benjamin, Grace Najjuka, SithembileBilima, Ibrahim Daud, Godfrey Musoro, Juliet Kitabalwa, George Selemani, Salome Kandie, K Magut Cornelius, ChrispusKatemba, Jay A Berkley, Amin S Hassan, Cissy Kityo, James Hakim, Robert S Heyderman, Diana M Gibb, A Sarah Walker, REALITY trial team JAIDS, September 2020 PMID: 33306556 
  19. Insulin resistance and intestinal integrity in children with and without HIV infection in Uganda.Dirajlal-Fargo S, Shan L, Sattar A, Bowman E, Gabriel J, Kulkarni M, Funderburg N, Nazzinda R, Musiime V, McComsey GA.HIV Med. 2020 Feb;21(2):119-127. doi: 10.1111/hiv.12808. Epub 2019 Oct 23.PMID: 31642582 
  20. Association of Kidney Disease with Abnormal Cardiac Structure and Function among Ugandans with HIV Infection.Peters M, Margevicius S, Kityo C, Mirembe G, Buggey J, Brinza E, Schluchter M, Yun C, Hung C, McComsey G, Longenecker C. J Acquir Immune DeficSyndr. 2020 Dec. PMID: 33044321. 
  21. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. Emmanuel Ndashimye, Mariano Avino, Abayomi S Olabode, Art F Y Poon, Richard M Gibson, Yue Li, Adam Meadows, Christine Tan, Paul S Reyes, Cissy M Kityo, Fred Kyeyune, Immaculate Nankya, Miguel E Quiñones-Mateu, Eric J Arts. J AntimicrobChemother.2020 Dec 1;75(12):3525-3533. doi: 10.1093/jac/dkaa355. PMID: 32853364 
  22. Monocyte Activation in Persons Living with HIV and Tuberculosis CoinfectionMoises A. Huaman, Steven M. Juchnowski, David A. Zidar, Cissy M. Kityo, Sophie Nalukwago, RashidahNazzinda, Carl J. Fichtenbaum, Chris T. Longenecker Dec. 2020.PMID: 33252496 
  23. Failure is not an Option: Barriers to HIV Treatment Adherence in Kampala, UgandaCorresponding author: Gabrielle Bruser, RitahKatasi, Lily Ziyue Zhang, Miriam Namasinga, Eric Arts, Cissy Kityo, Isaac Luginaah. Health Place. 2020. Dec 1;67:102481. Doi: 10.1016. PMID: 33276263 
  24. A Mixed Methods, Observational Investigation of Physical Activity, Exercise, and Diet Among Older Ugandans Living With and Without Chronic HIV Infection. Wright CH, Longenecker CT, Nazzindah R, Kityo C, Najjuuko T, Taylor K, Rentrope CR, Webel A. J Assoc Nurses AIDS Care. 2020 Dec 2. doi: 10.1097/JNC.0000000000000221. Epub ahead of print. PMID: 33273157. 
  25. The Association of Kidney Disease with Abnormal Cardiac Structure and Function among Ugandans with HIV InfectionMatthew Peters, SeungheeMargevicius, Cissy Kityo, Grace Mirembe, Jonathan Buggey, Ellen Brinza, Mark Schluchter, Chun-Ho Yun, Chung-Lieh Hung, Grace A McComsey, Chris T Longenecker. JAcquir Immune DeficSyndr. 2021 Jan 1;86(1):104-109 PMID: 33044321.

2019

  1. Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV. Fitzgerald FC, Lhomme E, Harris K, Kenny J, Doyle R, Kityo C, Shaw LP, Abongomera G, Musiime V, Cook A, Brown JR, Brooks A, Owen-Powell E, Gibb DM, Prendergast AJ, Sarah Walker A, Thiebaut R, Klein N; CHAPAS-3 Trial Team . J Infect Dis. 2019 Jan 1;219(1):89-100. doi: 10.1093/infdis/jiy495.
  2. First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda. Poon AFY, Ndashimye E, Avino M, Gibson R, Kityo C, Kyeyune F, Nankya I, Quiñones-Mateu ME, Arts EJ; The Ugandan Drug Resistance Study Team. AIDS Res Ther. 2019 Jan 22;16(1):3. doi: 10.1186/s12981-019-0218-2.
  3. Moving to Another World: Understanding the Impact of Clinical Trial Closure on Research Participants Living With HIV in Uganda.Nalubega S, Cox K, Mugerwa H, Evans C. J Assoc Nurses AIDS Care. 2019 Jan 17.doi: 10.1097/JNC.0000000000000057. [Epub ahead of print]
  4. Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators.Bansi-Matharu L, Loria GR, Cole SR, Mugerwa H, Vecino I, Lundgren J, Pulik P, Smith C, Phillips AN; INSIGHT START Study Group. AIDS. 2019 Mar 29. doi: 10.1097/QAD.0000000000002210. [Epub ahead of print] PMID: 30932953
  5. Impact of Integrase Inhibition compared to non-nucleoside inhibition on HIV reservoirs in Lymphoid Tissues.Rothenberger M, Nganou-Makamdop K, Kityo C, Ssali F, Chipman JG, Beilman GJ, Hoskuldsson T, Anderson J, Jasurda J, Schmidt TE, Calisto SP, Pearson H, Reimann T, David C, Perkey K, Southern P, Wietgrefe S, Helgeson E, Reilly C, Haase AT, Douek DC, Fletcher CV, Schacker TW. J Acquir Immune DeficSyndr. 2019 Mar 15. doi: 10.1097/QAI.0000000000002026. [Epub ahead of print]
  6. Perceptions of Strategies and Intervention Approaches for HIV Self-Management among Ugandan Adolescents: A Qualitative Study. Mutumba M, Mugerwa H, Musiime V, Gautam A, Nakyambadde H, Matama C, Stephenson R. J IntAssocProvid AIDS Care. 2019 Jan-Dec;18:2325958218823246. doi: 10.1177/2325958218823246. PMID:30798668
  7. Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation. Bourke CD, Gough EK, Pimundu G, Shonhai A, Berejena C, Terry L, Baumard L, Choudhry N, Karmali Y, Bwakura-Dangarembizi M, Musiime V, Lutaakome J, Kekitiinwa A, Mutasa K, Szubert AJ, Spyer MJ, Deayton JR, Glass M, Geum HM, Pardieu C, Gibb DM, Klein N, Edens TJ, Walker AS, Manges AR, Prendergast AJ. SciTransl Med. 2019 Apr 3;11(486). pii: eaav0537. doi: 10.1126/scitranslmed.aav0537. PMID: 30944164
  8. Subclinical Vascular Disease in Children with HIV in Uganda is Associated with Intestinal Barrier Dysfunction.Dirajlal-Fargo S, Albar Z, Bowman E, Labbato D, Sattar A, Karungi C, Longenecker CT, Nazzinda R, Funderburg N, Kityo C, Musiime V, McComsey GA. Clin Infect Dis. 2019 Dec 6. pii: ciz1141. doi: 10.1093/cid/ciz1141. [Epub ahead of print] PMID: 31807748
  9. Lessons for test and treat in an antiretroviral programme after decentralisation in Uganda: a retrospective analysis of outcomes in public healthcare facilities within the Lablite project.Kiwuwa-Muyingo S, Abongomera G, Mambule I, Senjovu D, Katabira E, Kityo C, Gibb DM, Ford D, Seeley J. Int Health. 2019 Nov 15. pii: ihz090. doi: 10.1093/inthealth/ihz090. [Epub ahead of print] PMID: 31730168
  10. Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min. Ross LL, Walker AS, Lou Y, Tenorio AR, Gibb DM, Double J, Gilks C, McCoig CC, Munderi P, Musoro G, Kityo CM, Grosskurth H, Hakim J, Mugyenyi PN, Cutrell A, Perger T, Shaefer MS. PLoS One. 2019 Nov 14;14(11):e0225199. doi: 10.1371/journal.pone.0225199. eCollection2019. PMID: 31725787
  11. Persistence of traditional and emergence of new structural drivers and factors for the HIV epidemic in rural Uganda; A qualitative study.Bajunirwe F, Akakimpa D, Tumwebaze FP, Abongomera G, Mugyenyi PN, Kityo PLoS One. 2019 Nov 6;14(11):e0211084. doi: 10.1371/journal.pone.0211084. eCollection2019. PMID: 31693660
  12. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.Kityo C, Hagins D, Koenig E, Avihingsanon A, Chetchotisakd P, Supparatpinyo K, Gankina N, Pokrovsky V, Voronin E, Stephens JL, DeJesus E, Wang H, Acosta RK, Cao H, Quirk E, Martin H, Makadzange T. J Acquir Immune DeficSyndr. 2019 Nov 1;82(3):321-328. doi: 10.1097/QAI.0000000000002137. PMID: 31609930
  13. HIV and pericardial fat are associated with abnormal cardiac structure and function among Ugandans.Buggey J, Yun L, Hung CL, Kityo C, Mirembe G, Erem G, Truong T, Ssinabulya I, Tang WHW, Hoit BD, McComsey GA, Longenecker CT. Heart. 2019 Sep 19. pii: heartjnl-2019-315346. doi: 10.1136/heartjnl2019-315346. [Epub ahead of print] PMID: 31537637
  14. Long-term virological outcomes, failure and acquired resistance in a large cohort of Ugandan children.Huibers MHW, Kityo C, Boerma RS, Kaudha E, Sigaloff KCE, Balinda SN, Bertagnolio S, Nakanjako R, Mugyenyi P, Calis JCJ, Boele van Hensbroek M, Rinke de Wit TF. J AntimicrobChemother. 2019 Oct 1;74(10):3035-3043. doi: 10.1093/jac/dkz266. PMID: 31289811
  15. Altered intestinal permeability and fungal translocation in Ugandan children with HIV.Dirajlal-Fargo S, El-Kamari V, Weiner L, Shan L, Sattar A, Kulkarni M, Funderburg N, Nazzinda R, Karungi C, Kityo C, Musiime V, McComsey GA. Clin Infect Dis. 2019 Jul 1. pii: ciz561. doi: 10.1093/cid/ciz561. [Epub ahead of print] PMID: 31260509
  16. Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.Ekenberg C, Tang MH, Zucco AG, Murray DD, MacPherson CR, Hu X, Sherman BT, Losso MH, Wood R, Paredes R, Molina JM, Helleberg M, Jina N, Kityo CM, Florence E, Polizzotto MN, Neaton JD, Lane HC, Lundgren JD. J Infect Dis. 2019 Sep 13;220(8):1325-1334. doi: 10.1093/infdis/jiz294. PMID:31219150
  17. Coronary artery calcium, HIV and inflammation in Uganda compared with the USA.Alencherry B, Erem G, Mirembe G, Ssinabulya I, Yun CH, Hung CL, Siedner MJ, Bittencourt M, Kityo C, McComsey GA, Longenecker CT. Open Heart. 2019 May 22;6(1):e001046. doi: 10.1136/openhrt-2019-001046. eCollection2019. PMID:31218009
  18. Plasma Biomarkers of Human Immunodeficiency Virus-Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy.Kroeze S, Wit FW, Rossouw TM, Steel HC, Kityo CM, Siwale M, Akanmu S, Mandaliya K, de Jager M, Ondoa P, Reiss P, Rinke de Wit TF, Kootstra N, Hamers RL. J Infect Dis. 2019 Aug 9;220(6):1029-1033. doi: 10.1093/infdis/jiz252. PMID: 31086991
  19. Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index. Shi Y, Thompson J, Walker AS, Paton NI, Cheung YB; EARNEST Trial Team. Health Qual Life Outcomes. 2019 May 10;17(1):83. doi: 10.1186/s12955-019-1135-8. PMID: 31077251
  20. Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial. Thompson JA, Kityo C, Dunn D, Hoppe A, Ndashimye E, Hakim J, Kambugu A, van Oosterhout JJ, Arribas J, Mugyenyi P, Walker AS, Paton NI; Europe–Africa Research Network for Evaluation of Second line Therapy (EARNEST) Trial Team . Clin Infect Dis. 2019 Mar 19;68(7):1184-1192. doi: 10.1093/cid/ciy589. PMID: 30060027
  21. Prevalence of non-communicable diseases among HIV positive patients on antiretroviral therapy at joint clinical research centre, Lubowa, Uganda. Kansiime S, Mwesigire D, Mugerwa PLoS One. 2019 Aug 9;14(8):e0221022. doi: 10.1371/journal.pone.0221022. eCollection2019. PMID: 31398244
  22. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, WangariNdege B, NeretteFontain S, Samaneka W, Secours R, van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Avihingsanon A, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC; A5288 Team. Lancet HIV. 2019 Sep;6(9):e588-e600. doi: 10.1016/S2352-3018(19)30146-8. Epub2019 Jul 29. PMID: 31371262
  23. Perceptions of HIV Self-Management Roles and Challenges in Adolescents, Caregivers, and Health Care Providers. Mutumba M, Musiime V, Mugerwa H, Nakyambadde H, Gautam A, Matama C, Stephenson R. J Assoc Nurses AIDS Care. 2019 Jul-Aug;30(4):415-427. doi: 10.1097/JNC.0000000000000011. PMID: 31241506
  24. Insulin resistance and intestinal integrity in children with and without HIV infection in Uganda.Dirajlal-Fargo S, Shan L, Sattar A, Bowman E, Gabriel J, Kulkarni M, Funderburg N, Nazzinda R, Musiime V, McComsey GA. HIV Med. 2019 Oct 23. doi: 10.1111/hiv.12808. [Epub ahead of print] PMID: 31642582
  25. Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.Penazzato M, Townsend CL, Rakhmanina N, Cheng Y, Archary M, Cressey TR, Kim MH, Musiime V, Turkova A, Ruel TD, Rabie H, Sugandhi N, Rojo P, Doherty M, Abrams EJ; PADO4 participants. Lancet HIV. 2019 Sep;6(9):e623-e631. doi: 10.1016/S2352-3018(19)30193-6. Review. PMID: 31498110
  26. Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial. Gross R, Ritz J, Hughes MD, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Godfrey C, Wallis CL, Mellors JW, Mudhune VO, Badal-Faesen S, Grinsztejn B, Collier AC. Lancet Digit Health. 2019 May;1(1):e26-e34. doi: 10.1016/S2589-7500(19)30006-8. Epub2019 May 6. PMID: 31528850

2018

  1. Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial. Siika A, McCabe L, Bwakura-Dangarembizi M, Kityo C, Mallewa J, Berkley J, Maitland K, Griffiths A, Baleeta K, Mudzingwa S, Abach J, Nathoo K, Thomason MJ, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team .Clin Infect Dis. 2018 Mar 4;66(suppl_2):S140-S146. doi: 10.1093/cid/cix1142. PMID:29514235
  2. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Lancet Infect Dis. 2018 Jan;18(1):47-57. doi: 10.1016/S1473-3099(17)30630-8. Epub 2017 Nov 3.PMID:29108797
  3. HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa. Hoppe A, Giuliano M, Lugemwa A, Thompson JA, Floridia M, Walker AS, Senoga I, Abwola MC, Pirillo MF, Kityo CM, Arenas-Pinto A, Paton NI; EARNEST Trial Team.Antivir Ther. 2018;23(2):191-195. doi: 10.3851/IMP3200. PMID:29021409.
  4. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women. Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H. J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):209-213. doi: 10.1097/QAI.0000000000001663. PMID:29481486
  5. A Human-Centered Approach to CV Care: Infrastructure Development in Uganda. Longenecker CT, Kalra A, Okello E, Lwabi P, Omagino JO, Kityo C, Kamya MR, Webel AR, Simon DI, Salata RA, Costa MA. Glob Heart. 2018 Apr 20. pii: S2211-8160(18)30022-X. doi: 10.1016/j.gheart.2018.02.002. [Epub ahead of print] PMID:29685638
  6. Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda. Ndashimye E, Avino M, Kyeyune F, Nankya I, Gibson RM, Nabulime E, Poon AFY, Kityo C, Mugyenyi P, Quiñones-Mateu ME, Arts EJ. AIDS Res Hum Retroviruses. 2018 May;34(5):404-414. doi: 10.1089/AID.2017.0205. Epub 2018 Feb 26. PMID:29353487
  7. Lymphoid tissue fibrosis is associated with impaired vaccine responses. Kityo C, Makamdop KN, Rothenberger M, Chipman JG, Hoskuldsson T, Beilman GJ, Grzywacz B, Mugyenyi P, Ssali F, Akondy RS, Anderson J, Schmidt TE, Reimann T, Callisto SP, Schoephoerster J, Schuster J, Muloma P, Ssengendo P, Moysi E, Petrovas C, Lanciotti R, Zhang L, Arévalo MT, Rodriguez B, Ross TM, Trautmann L, Sekaly RP, Lederman MM, Koup RA, Ahmed R, Reilly C, Douek DC, Schacker TW. J Clin Invest. 2018 May 21. pii: 97377. doi: 10.1172/JCI97377. [Epub ahead of print] PMID:29781814
  8. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. Kroeze S, Ondoa P, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, de Pundert ME, Sigaloff KCE, Reiss P, Wit FWNM, Rinke de Wit TF, Hamers RL. AIDS. 2018 May 15;32(8):1043-1051. doi: 10.1097/QAD.0000000000001801 PMID:29547445
  9. Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda. Abongomera G, Chiwaula L, Revill P, Mabugu T, Tumwesige E, Nkhata M, Cataldo F, van Oosterhout J, Colebunders R, Chan AK, Kityo C, Gilks C, Hakim J, Seeley J, Gibb DM, Ford D. Int Health. 2018 Jan 1;10(1):8-19. doi: 10.1093/inthealth/ihx061. PMID:29329396
  10. Towards 90-90-90 Target: Factors Influencing Availability, Access, and Utilization of HIV Services-A Qualitative Study in 19 Ugandan Districts. Bajunirwe F, Tumwebaze F, Akakimpa D, Kityo C, Mugyenyi P, Abongomera G. Biomed Res Int. 2018 Mar 21;2018:9619684. doi: 10.1155/2018/9619684. eCollection 2018. PMID:29750175
  11. She knows that she will not come back: tracing patients and new thresholds of collective surveillance in PMTCT OptionCataldo F, Seeley J, Nkhata MJ, Mupambireyi Z, Tumwesige E, Gibb DM; Lablite team. BMC Health Serv Res. 2018 Feb 1;18(1):76. doi: 10.1186/s12913-017-2826-7. PMID:29391055
  12. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial. Mallewa J, Szubert AJ, Mugyenyi P, Chidziva E, Thomason MJ, Chepkorir P, Abongomera G, Baleeta K, Etyang A, Warambwa C, Melly B, Mudzingwa S, Kelly C, Agutu C, Wilkes H, Nkomani S, Musiime V, Lugemwa A, Pett SL, Bwakura-Dangarembizi M, Prendergast AJ, Gibb DM, Walker AS, Berkley JA; REALITY trial team. Lancet HIV. 2018 May;5(5):e231-e240. doi: 10.1016/S2352-3018(18)30038-9. Epub 2018 Apr 10. Erratum in: Lancet HIV. 2018 May 29. PMID:29653915
  13. Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial. Post FA, Szubert AJ, Prendergast AJ, Johnston V, Lyall H, Fitzgerald F, Musiime V, Musoro G, Chepkorir P, Agutu C, Mallewa J, Rajapakse C, Wilkes H, Hakim J, Mugyenyi P, Walker AS, Gibb DM, Pett SL; Reduction of EArly mortaLITY in HIV-infected adults and children starting antiretroviral therapy (REALITY) Trial Team . Clin Infect Dis. 2018 Mar 4;66(suppl_2):S132-S139. doi: 10.1093/cid/cix1141. PMID:29514234
  14. When prevention of mother-to-child HIV transmission fails: preventing pretreatment drug resistance in African children. Inzaule SC, Hamers RL, Calis J, Boerma R, Sigaloff K, Zeh C, Mugyenyi P, Akanmu S, Rinke de Wit TF. AIDS. 2018 Jan 14;32(2):143-147. doi: 10.1097/QAD.0000000000001696. No abstract available. PMID:29135578
  15. Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection. Klein K, Nickel G, Nankya I, Kyeyune F, Demers K, Ndashimye E, Kwok C, Chen PL, Rwambuya S, Poon A, Munjoma M, Chipato T, Byamugisha J, Mugyenyi P, Salata RA, Morrison CS, Arts EJ. PLoS Pathog. 2018 Jan 18;14(1):e1006754. doi: 10.1371/journal.ppat.1006754. eCollection 2018PMID: 29346424
  16. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial. Turkova A, Moore CL, Butler K, Compagnucci A, Saïdi Y, Musiime V, Nanduudu A, Kaudha E, Cressey TR, Chalermpantmetagul S, Scott K, Harper L, Montero S, Riault Y, Bunupuradah T, Volokha A, Flynn PM, Bologna R, Ramos Amador JT, Welch SB, Nastouli E, Klein N, Giaquinto C, Ford D, Babiker A, Gibb DM; BREATHER (PENTA 16) trial Group. PLoS One. 2018 Apr 23;13(4):e0196239. doi: 10.1371/journal.pone.0196239. eCollection 2018. PMID: 29684092
  17. Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda. Ndashimye E, Avino M, Kyeyune F, Nankya I, Gibson RM, Nabulime E, Poon AFY, Kityo C, Mugyenyi P, Quiñones-Mateu ME, Arts EJ AIDS Res Hum Retroviruses. 2018 May;34(5):404-414. doi: 10.1089/AID.2017.0205. Epub 2018 Feb 26. PMID: 29353487.
  18. Efficacy and Safety of Switching to CoformulatedElvitegravir, Cobicistat, Emtricitabine, and TenofovirAlafenamide (E/C/F/Taf) in Virologically Suppressed Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H. J Acquir Immune DeficSyndr. 2018 Feb 21. Doi: 10.1097/QAI.0000000000001663. Epub ahead of print
  19. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial. Kityo C, Szubert AJ, Siika A, Heyderman R, Bwakura-Dangarembizi M, Lugemwa A, Mwaringa S, Griffiths A, Nkanya I, Kabahenda S, Wachira S, Musoro G, Rajapakse C, Etyang T, Abach J, Spyer MJ, Wavamunno P, Nyondo-Mipando L, Chidziva E, Nathoo K, Klein N, Hakim J, Gibb DM, Walker AS, Pett SL; REALITY trial team. PLoS Med. 2018 Dec 4;15(12):e1002706. doi: 10.1371/journal.pmed.1002706. eCollection 2018 PMID: 30513108
  20. Utilization of “prevention of mother-to-child transmission" of HIV services by adolescent and young mothers in Mulago Hospital, Uganda. Mustapha M, Musiime V, Bakeera-Kitaka S, Rujumba J, Nabukeera-Barungi N. BMC Infect Dis. 2018 Nov 14;18(1):566. doi: 10.1186/s12879-018-3480-3. PMID: 30428835
  21. Smoking and Accelerated Lung Function Decline in HIV-Positive Individuals: A Secondary Analysis of the START Pulmonary Substudy. MacDonald DM, Melzer AC, Collins G, Avihingsanon A, Crothers K, Ingraham NE, Mugerwa H, Ristola M, Shuter J, Kunisaki KM; INSIGHT START Pulmonary Substudy Group. J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):e85-e92. doi: 10.1097/QAI.0000000000001797. PMID:29985804
  22. Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV. Ford D, Turner R, Turkova A, Penazzato M, Musiime V, Bwakura-Dangarembizi M, Violari A, Chabala C, Puthanakit T, Sudjaritruk T, Cressey TR, Lallemant M, Gibb DM. J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1:S40-S48. doi: 10.1097/QAI.0000000000001748. PMID: 29994919
  23. Evolution of protease inhibitor resistance in HIV-1-infected patients failing protease inhibitor monotherapy as second-line therapy in low-income countries: an observational analysis within the EARNEST randomised trial. Thompson JA, Kityo C, Dunn D, Hoppe A, Ndashimye E, Hakim J, Kambugu A, van Oosterhout JJ, Arribas J, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Clin Infect Dis. 2018 Jul 28. doi: 10.1093/cid/ciy589. [Epub ahead of print] PMID: 30060027
  24. Microbial translocation does not drive immune activation in Ugandan children with HIV. Fitzgerald FC, Lhomme E, Harris K, Kenny J, Doyle R, Kityo C, Shaw LP, Abongomera G, Musiime V, Cook A, Brown JR, Brooks A, Owen-Powell E, Gibb DM, Prendergast AJ, Walker AS, Thiebaut R, Klein N; CHAPAS-3 Trial Team. J Infect Dis. 2018 Aug 11. doi: 10.1093/infdis/jiy495. [Epub ahead of print]: PMID:30107546
  25. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Inzaule SC, Hamers RL, Noguera-Julian M, Casadellà M, Parera M, Kityo C, Steegen K, Naniche D, Clotet B, Rinke de Wit TF, Paredes R; PanAfrican Studies to Evaluate Resistance. Lancet HIV. 2018 Sep 28. pii: S2352-3018(18)30177-2. doi: 10.1016/S2352-3018(18)30177-2. [Epub ahead of print] PMID: 30282603
  26. Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance. Inzaule SC, Kityo CM, Siwale M, Akanmu AS, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, Ondoa P, Sigaloff KCE, Naniche D, Rinke de Wit TF, Hamers RL. Sci Rep. 2018 Oct 25;8(1):15751. doi: 10.1038/s41598-018-33538-0. PMID: 30361640
  27. Long-term safety of the elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate single-tablet regimen in treatment-naïve women: week 96 results: Cissy Kityo MD, Kathleen Squires MD, Sally Hodder MD, Debbie Hagins MD, Anchalee Avihingsanon MD, YuliaPlotnikova MD, Ellen Koenig MD, Frank A. Post MD, Angela DM Kashuba MD, Anna Kido BS, Rima Kulkarni PhD, Shuping Jiang PhD, Huyen Cao MD – submitted to HIV clinical trials in October 2018
  28. Plasma biomarkers of HIV-related systemic inflammation and immune activation in sub-Saharan Africa before and during suppressive antiretroviral therapy: Stefanie Kroeze, Ferdinand W. Wit, Theresa M. Rossouw, Helen C. Steel, Cissy M. Kityo, Margaret Siwale, Sulaimon Akanmu, Kishor Mandaliya, Marleen de Jager, Pascale Ondoa,  Peter Reiss, Tobias F. Rinke de Wit, Neeltje Kootstra, Raph L. Hamers. – submitted to Journal of Infectious diseases in November 2018

2017

  1. Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure. Boerma RS, Bunupuradah T, Dow D, Fokam J, Kariminia A, Lehman D, Kityo C, Musiime V, Palumbo P, Schoffelen A, Sophan S, Zanoni B, Rinke de Wit TF, Calis JCJ, Sigaloff KCE; Paediatric Second-line Study Group. Int AIDS Soc. 2017 Sep 15;20(1):21930. doi: 10.7448/IAS.20.1.21930.
  2. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Lancet Infect Dis. 2017 Nov 3. pii: S1473-3099(17)30630-8. doi: 10.1016/S1473-3099(17)30630-8
  3. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa. Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, Walker S, Pett SL, Bwakura-Dangarembizi M, Lugemwa A, Kaunda S, Karoney M, Musoro G, Kabahenda S, Nathoo K, Maitland K, Griffiths A, Thomason MJ, Kityo C, Mugyenyi P, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team.N Engl J Med. 2017 Jul 20;377(3):233-245. doi: 10.1056/NEJMoa1615822.
  4. Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation. Barlow-Mosha L, Musiime V, Davies MA, Prendergast AJ, Musoke P, Siberry G, Penazzato M. J Int AIDS Soc. 2017 Jun 27;20(1):21552. doi: 10.7448/IAS.20.1.21552.
  5. Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children. Kityo C, Boerma RS, Sigaloff KCE, Kaudha E, Calis JCJ, Musiime V, Balinda S, Nakanjako R, Boender TS, Mugyenyi PN, Rinke de Wit TF. J AntimicrobChemother. 2017 Sep 1;72(9):2587-2595. doi: 10.1093/jac/dkx188.
  6. Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children. Kekitiinwa A, Szubert AJ, Spyer M, Katuramu R, Musiime V, Mhute T, Bakeera-Kitaka S, Senfuma O, Walker AS, Gibb DM; ARROW Trial Team. Pediatr Infect Dis J. 2017 Jun;36(6):588-594. doi:10.1097/INF.0000000000001505.
  7. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub2017 May 8.
  8. Unmet needs persist in pediatric HIV programs: lessons from selected case studies in Uganda. Orikiiriza J, Nakawesi J, Kikaire B, Turitwenka D, Schlech W, Kambugu A, Lamorde M, Normark J, Hennessy M, Musiime V, Rujumba J, Ndeezi G, Tumwesigye NM, Doherty DG, Achan J. AIDS. 2017 May 15;31(8):1196-1199. doi: 10.1097/QAD.0000000000001436. No abstract available.
  9. Impact of decentralization of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys. Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips AN, Katabira E, Chan AK, Gilks C, Musiime V, Hakim J, Kityo C, Colebunders R, Gibb DM, Seeley J, Ford D; Lablite Project Team. Int Health. 2017 Mar 1;9(2):91-99. doi: 10.1093/inthealth/ihx006.
  10. Psychological distress among Ugandan adolescents living with HIV: Examining stressors and the buffering role of general and religious coping strategies. Mutumba M, Bauermeister JA, Harper GW, Musiime V, Lepkowski J, Resnicow K, Snow RC. Glob Public Health. 2017 Dec;12(12):1479-1491. doi: 10.1080/17441692.2016.1170871. Epub 2016 Apr 11.
  11. Insulin Resistance and Markers of Inflammation in HIV-infected Ugandan Children in the CHAPAS-3 Trial. Dirajlal-Fargo S, Musiime V, Cook A, Mirembe G, Kenny J, Jiang Y, Debanne S, Klein N, McComsey GA. Pediatr Infect Dis J. 2017 Aug;36(8):761-767. doi: 10.1097/INF.0000000000001544.
  12. Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa. Abongomera G, Cook A, Musiime V, Chabala C, Lamorde M, Abach J, Thomason M, Mulenga V, Kekitiinwa A, Colebunders R, Kityo C, Walker AS, Gibb DM. AIDS Behav. 2017 Feb;21(2):441-449. doi: 10.1007/s10461-016-1582-8.
  13. Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance. Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugyenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KCE, Calis JCJ. J Trop Pediatr. 2017 Apr 1;63(2):135-143. doi: 10.1093/tropej/fmw062. Erratum in: J Trop Pediatr. 2016 Oct 15;:null.
  14. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa. Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, Walker S, Pett SL, Bwakura-Dangarembizi M, Lugemwa A, Kaunda S, Karoney M, Musoro G, Kabahenda S, Nathoo K, Maitland K, Griffiths A, Thomason MJ, Kityo C, Mugyenyi P, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team. N Engl J Med. 2017 Jul 20;377(3):233-245. doi: 10.1056/NEJMoa1615822.
  15. The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data. Dolling DI, Goodall RL, Chirara M, Hakim J, Nkurunziza P, Munderi P, Eram D, Tumukunde D, Spyer MJ, Gilks CF, Kaleebu P, Dunn DT, Pillay D; DART Virology Group. BMC Infect Dis. 2017 Feb 21;17(1):160. doi: 10.1186/s12879-017-2266-3.
  16. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa. Kityo C, Thompson J, Nankya I, Hoppe A, Ndashimye E, Warambwa C, Mambule I, van Oosterhout JJ, Wools-Kaloustian K, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Acquir Immune DeficSyndr. 2017 Jun 1;75(2):e45-e54. doi: 10.1097/QAI.0000000000001285.
  17. Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance. Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugyenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KCE, Calis JCJ. J Trop Pediatr. 2017 Apr 1;63(2):135-143. doi: 10.1093/tropej/fmw062. Erratum in: J Trop Pediatr. 2016 Oct 15;:null.
  18. Monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Lancet Infect Dis. 2017 Nov 3. pii: S1473-3099(17)30630-8. doi: 10.1016/S1473-3099(17)30630-8.
  19. Implementation of Antiretroviral Therapy for Life in Pregnant/Breastfeeding HIV+ Women (Option B+) Alongside Rollout and Changing Guidelines for ART Initiation in Rural Zimbabwe: The Lablite Project Experience. Ford D, Muzambi M, Nkhata MJ, Abongomera G, Joseph S, Ndlovu M, Mabugu T, Grundy C, Chan AK, Cataldo F, Kityo C, Seeley J, Katabira E, Gilks CF, Reid A, Hakim J, Gibb DM; Lablite Team. J Acquir Immune DeficSyndr. 2017 Apr 15;74(5):508-516. doi: 10.1097/QAI.0000000000001267.
  20. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa. Kityo C, Thompson J, Nankya I, Hoppe A, Ndashimye E, Warambwa C, Mambule I, van Oosterhout JJ, Wools-Kaloustian K, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. J Acquir Immune DeficSyndr. 2017 Jun 1;75(2):e45-e54. doi: 10.1097/QAI.0000000000001285.
  21. HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.Hoppe A, Giuliano M, Lugemwa A, Thompson JA, Floridia M, Walker AS, Senoga I, Abwola MC, Pirillo MF, Kityo CM, Arenas-Pinto A, Paton NI; EARNEST Trial Team.AntivirTher. 2017 Oct 11. doi: 10.3851/IMP3200. [Epub ahead of print]PMID:29021409
  22. Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance. Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugyenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KCE, Calis JCJ. J Trop Pediatr. 2017 Apr 1;63(2):135-143. doi: 10.1093/tropej/fmw062. Erratum in: J Trop Pediatr. 2016 Oct 15;:null.
  23. Factors influencing cigarette smoking among soldiers and costs of soldier smoking in the work place at Kakiri Barracks, Uganda. Basaza R, Otieno E, Musinguzi A, Mugyenyi P, Haddock CK. Tob Control. 2017 May;26(3):330-333. doi: 10.1136/tobaccocontrol-2015-052878. Epub 2016 May 10.
  24. Long-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative Study. Inzaule SC, Hamers RL, Kityo C, Rinke de Wit TF, RouraM.PLoS One. 2017 Feb 8;12(2):e0172077. doi: 10.1371/journal.pone.0172077. eCollection2017.PMID:28178336
  25. Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa Goodall RL, Dunn DT, Nkurunziza P, Mugarura L, Pattery T, Munderi P, Kityo C, Gilks C, Kaleebu P, Pillay D, Gupta RK; DART Virology Group.JAntimicrobChemother. 2017 May 1;72(5):1450-1455. doi: 10.1093/jac/dkw583.PMID:28160504.
  26. Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H.AIDS. 2017 Apr 24;31(7):905-915. doi: 10.1097/QAD.0000000000001376.PMID:28060017.
  27. Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. Bienczak A, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Walker AS, Owen A, Gibb DM, Burger D, McIlleron H, Denti P.J AntimicrobChemother. 2017 Jan;72(1):190-199. Epub 2016 Oct 5.PMID:27707991.
  28. Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts. Bijker R, Jiamsakul A, Kityo C, Kiertiburanakul S, Siwale M, Phanuphak P, Akanmu S, Chaiwarith R, Wit FW, Sim BL, Boender TS, Ditangco R, Rinke De Wit TF, Sohn AH, Hamers RL.J Int AIDS Soc. 2017 Mar 3;20(1):1-10. doi: 10.7448/IAS.20.1.21218.PMID:28362063
  29. Defining total-body AIDS-virus burden with implications for curative strategies. Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, Deeks SG, Luciw PA, Chipman JG, Beilman GJ, Hoskuldsson T, Khoruts A, Anderson J, Deleage C, Jasurda J, Schmidt TE, Hafertepe M, Callisto SP, Pearson H, Reimann T, Schuster J, Schoephoerster J, Southern P, Perkey K, Shang L, Wietgrefe SW, Fletcher CV, Lifson JD, Douek DC, McCune JM, Haase AT, SchackerTW.Nat Med. 2017 Oct 2. doi: 10.1038/nm.4411.
  30. Hepatitis B serological markers and plasma DNA concentrations. Price H, Dunn D, Zachary T, Vudriko T, Chirara M, Kityo C, Munderi P, Spyer M, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R; DART Virology Group.AIDS. 2017 May 15;31(8):1109-1117. doi: 10.1097/QAD.0000000000001454.PMID:28328795

2016

  1. Neuroscience and awareness in the dying human brain: Implications for organ donation practices. Rady MY, Verheijde JL. J Crit Care. 2016 Aug;34:121-3. doi: 10.1016/j.jcrc.2016.04.016. Epub 2016 Apr 26.
  2. Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. Kekitiinwa A, Musiime V, Thomason MJ, Mirembe G, Lallemant M, Nakalanzi S, Baptiste D, Walker AS, Gibb DM, Judd A. Antivir Ther. 2016 Apr 29. doi: 10.3851/IMP3054.
  3. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. Castellsagué X, Alemany L, Quer M, Halec G, Quirós B, Tous S, Clavero O, Alòs L, Biegner T, Szafarowski T, Alejo M, Holzinger D, Cadena E, Claros E, Hall G, Laco J, Poljak M, Benevolo M, Kasamatsu E, Mehanna H, Ndiaye C, Guimerà N, Lloveras B, León X, Ruiz-Cabezas JC, Alvarado-Cabrero I, Kang CS, Oh JK, Garcia-Rojo M, Iljazovic E, Ajayi OF, Duarte F, Nessa A, Tinoco L, Duran-Padilla MA, Pirog EC, Viarheichyk H, Morales H, Costes V, Félix A, Germar MJ, Mena M, Ruacan A, Jain A, Mehrotra R, Goodman MT, Lombardi LE, Ferrera A, Malami S, Albanesi EI, Dabed P, Molina C, López-Revilla R, Mandys V, González ME, Velasco J, Bravo IG, Quint W, Pawlita M, Muñoz N, de Sanjosé S, Xavier Bosch F; ICO International HPV in Head and Neck Cancer Study Group. J Natl Cancer Inst. 2016 Jan 28;108(6):djv403. doi: 10.1093/jnci/djv403. Print 2016
  4. HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda. Kityo C, Sigaloff KC, Sonia Boender T, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde-Katumba L, Calis JC, Rinke de Wit TF, Mugyenyi PN. AIDS Res Hum Retroviruses. 2016 Jul;32(7):628-35. doi: 10.1089/AID.2015.0215. Epub 2016 Feb 11.
  5. Cardiac Dysfunction Among Ugandan HIV-infected Children on Antiretroviral Therapy. Namuyonga J, Lubega S, Musiime V, Lwabi P, Lubega I. Pediatr Infect Dis J. 2016 Mar;35(3):e85-8. doi: 10.1097/INF.0000000000000997.
  6. Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial. Arenas-Pinto A, Thompson J, Musoro G, Musana H, Lugemwa A, Kambugu A, Mweemba A, Atwongyeire D, Thomason MJ, Walker AS, Paton NI; EARNEST Trial Team. J Neurovirol. 2016 Feb;22(1):104-13. doi: 10.1007/s13365-015-0374-7. Epub 2015 Aug 25.
  7. Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. Bienczak A, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Walker AS, Owen A, Gibb DM, Burger D, McIlleron H, Denti P. J Antimicrob Chemother. 2016 Oct 5. pii: dkw388.
  8. Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance. Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugyenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KC, Calis JC. J Trop Pediatr. 2016 Sep 15. pii: fmw062.
  9. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, Avihingsanon A, Koenig E, Jiang S, White K, Cheng A, Szwarcberg J, Cao H. Lancet HIV. 2016 Sep;3(9):e410-20. doi: 10.1016/S2352-3018(16)30016-9. Epub 2016 May 27.
  10. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. Boender TS, Hamers RL, Ondoa P, Wellington M, Chimbetete C, Siwale M, Labib Maksimos EE, Balinda SN, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Stevens W, Rinke de Wit TF, Sigaloff KC. J Infect Dis. 2016 Sep 15;214(6):873-83. doi: 10.1093/infdis/jiw219. Epub 2016 Jul 11.
  11. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, Siwale M, Nankya I, Kaudha E, Akanmu AS, Botes ME, Steegen K, Calis JC, Rinke de Wit TF, Sigaloff KC. J Antimicrob Chemother. 2016 Oct;71(10):2918-27. doi: 10.1093/jac/dkw218. Epub 2016 Jun 23.
  12. Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial. Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks CF, Goodall R, Spyer M, Kityo C, Pillay D, Gupta RK; DART Virology Group. PLoS One. 2016 Jun 2;11(6):e0157094. doi: 10.1371/journal.pone.0157094. eCollection 2016.
  13. Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children. Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H. J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):161-8. doi: 10.1097/QAI.0000000000001032.
  14. Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda. Bajunirwe F, Tumwebaze F, Abongomera G, Akakimpa D, Kityo C, Mugyenyi PN. BMC Res Notes. 2016 Apr 14;9:217. doi: 10.1186/s13104-016-2024-4.
  15. Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure. Kyeyune F, Gibson RM, Nankya I, Venner C, Metha S, Akao J, Ndashimye E, Kityo CM, Salata RA, Mugyenyi P, Arts EJ, Quiñones-Mateu ME. Antimicrob Agents Chemother. 2016 May 23;60(6):3380-97. doi: 10.1128/AAC.00038-16. Print 2016
  16. The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. Bienczak A, Cook A, Wiesner L, Olagunju A, Mulenga V, Kityo C, Kekitiinwa A, Owen A, Walker AS, Gibb DM, McIlleron H, Burger D, Denti P. Br J Clin Pharmacol. 2016 Jul;82(1):185-98. doi: 10.1111/bcp.12934. Epub 2016 Apr 25.
  17. Clinical Evaluation of an Affordable Qualitative Viral Failure Assay for HIV Using Dried Blood Spots in Uganda. Balinda SN, Ondoa P, Obuku EA, Kliphuis A, Egau I, Bronze M, Kasambula L, Schuurman R, Spieker N, Rinke de Wit TF, Kityo C; ART–A consortium. PLoS One. 2016 Jan 29;11(1):e0145110. doi: 10.1371/journal.pone.0145110. eCollection 2016.
  18. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team. Lancet Infect Dis. 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5.
  19. Brief Report: Prevalence of Latent Rheumatic Heart Disease Among HIV-Infected Children in Kampala, Uganda. Gleason B, Mirembe G, Namuyonga J, Okello E, Lwabi P, Lubega I, Lubega S, Musiime V, Kityo C, Salata RA, Longenecker CT. J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):196-9. doi: 10.1097/QAI.0000000000000827.
  20. Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis. Prendergast AJ, Bwakura-Dangarembizi M, Mugyenyi P, Lutaakome J, Kekitiinwa A, Thomason MJ, Gibb DM, Walker AS; ARROW Trial Team. AIDS. 2016 Sep 20.
  21. Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. Borges ÁH, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, Mugyenyi P, Domingo P, Hoffmann C, Read TR, Pujari S, Meulbroek M, Johnson M, Wilkin T, Mitsuyasu R; INSIGHT START Study Group. Clin Infect Dis. 2016 Sep 8. pii: ciw621.
  22. Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa. Inzaule SC, Ondoa P, Peter T, Mugyenyi PN, Stevens WS, de Wit TF, Hamers RL. Lancet Infect Dis. 2016 Aug 25. pii: S1473-3099(16)30118-9. doi: 10.1016/S1473-3099(16)30118-9.
  23. Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy. Prendergast AJ, Szubert AJ, Berejena C, Pimundu G, Pala P, Shonhai A, Musiime V, Bwakura-Dangarembizi M, Poulsom H, Hunter P, Musoke P, Kihembo M, Munderi P, Gibb DM, Spyer M, Walker AS, Klein N; ARROW Trial Team. J Infect Dis. 2016 Jul 15;214(2):226-36. doi: 10.1093/infdis/jiw148. Epub 2016 May 18.
  24. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, Kirui FK, Badal-Faesen S, Lagat D, Nyirenda M, Naidoo K, Hakim J, Mugyenyi P, Henostroza G, Leger PD, Lama JR, Mohapi L, Alave J, Mave V, Veloso VG, Pillay S, Kumarasamy N, Bao J, Hogg E, Jones L, Zolopa A, Kumwenda J, Gupta A; Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Lancet. 2016 Mar 19;387(10024):1198-209. doi: 10.1016/S0140-6736(16)00546-8.
  25. Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugyenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team. BMC Med. 2016 Mar 23;14:50. doi: 10.1186/s12916-016-0593-7.
  26. Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance. Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugyenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KC, Calis JC. J Trop Pediatr. 2016 Sep 15. pii: fmw062.
  27. Examining the relationship between psychological distress and adherence to anti-retroviral therapy among Ugandan adolescents living with HIV. Mutumba M, Musiime V, Lepkwoski JM, Harper GW, Snow RC, Resnicow K, Bauermeister JA. AIDS Care. 2016 Jul;28(7):807-15. doi: 10.1080/09540121.2015.1131966. Epub 2016 Jan 10.
  28. Once vs twice-daily abacavir and lamivudine in African children. Musiime V, Kasirye P, Naidoo-James B, Nahirya-Ntege P, Mhute T, Cook A, Mugarura L, Munjoma M, Thoofer NK, Ndashimye E, Nankya I, Spyer MJ, Thomason MJ, Snowden W, Gibb DM, Walker AS; ARROW Trial Team. AIDS. 2016 Jul 17;30(11):1761-70. doi: 10.1097/QAD.0000000000001116.
  29. Can abacavir be used safely in children without HLA testing? Musiime V, Prendergast AJ. Lancet HIV. 2016 Feb;3(2):e58-9. doi: 10.1016/S2352-3018(15)00228-3. Epub 2015 Dec 7. No abstract available.

2015

  1. Communicating vaccine safety in the context of immunization programs in low resource settings. Arwanire EM, Mbabazi W, Mugyenyi Curr Drug Saf. 2015;10(1):68-75.
  2. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227. No abstract available.
  3. Opportunities for improving the efficiency of paediatric HIV treatment programmes. Revill PA, Walker S, Mabugu T, Nathoo KJ, Mugyenyi P, Kekitinwa A, Munderi P, Bwakura-Dangarembizi M, Musiime V, Bakeera-Kitaka S, Nahirya-Ntege P, Walker AS, Sculpher MJ, Gibb DM. AIDS. 2015 Jan 14;29(2):201-10. doi: 10.1097/QAD.0000000000000518.
  4. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugyenyi P, Nahirya P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team. Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491.
  5. Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Kunisaki KM, Niewoehner DE, Collins G, Nixon DE, Tedaldi E, Akolo C, Kityo C, Klinker H, La Rosa A, Connett JE; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. HIV Med. 2015 Apr;16 Suppl 1:119-28. doi: 10.1111/hiv.12240.
  6. HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels. Eller MA, Opollo MS, Liu M, Redd AD, Eller LA, Kityo C, Kayiwa J, Laeyendecker O, Wawer MJ, Milazzo M, Kiwanuka N, Gray RH, Serwadda D, Sewankambo NK, Quinn TC, Michael NL, Wabwire-Mangen F, Sandberg JK, Robb ML. J Infect Dis. 2015 May 15;211(10):1574-84. doi: 10.1093/infdis/jiu646. Epub 2014 Nov 17.
  7. Prevalence of hepatitis B and C and relationship to liver damage in HIV infected patients attending Joint Clinical Research Centre Clinic (JCRC), Kampala, Uganda. Baseke J, Musenero M, Mayanja-Kizza H. Afr Health Sci. 2015 Jun;15(2):322-7. doi: 10.4314/ahs.v15i2.3.
  8. Inguinal lymph node and anorectal mucosal biopsies for human immunodeficiency virus research protocols in an emerging nation: patient outcomes and lessons learned. Rothenberger MK, Mutuluuza CK, Ssali F, Jasurda J, Schmidt T, Schacker TW, Beilman GJ, Chipman JG. Surg Infect (Larchmt). 2015 Feb;16(1):68-71. doi: 10.1089/sur.2013.179. Epub 2015 Feb 4.
  9. Partner-Focused Adherence Intervention for Second-line Antiretroviral Therapy: A Multinational Randomized Trial (ACTG A5234). Gross R, Zheng L, La Rosa A, Sun X, Rosenkranz SL, Cardoso SW, Ssali F, Camp R, Godfrey C, Cohn SE, Robbins GK, Chisada A, Wallis CL, Reynolds NR, Lu D, Safren SA, Hosey L, Severe P, Collier AC. Lancet HIV. 2015 Jan 1;2(1):e12-e19.
  10. Disclosure of HIV Status to Perinatally Infected Adolescents in Urban Uganda: A Qualitative Study on Timing, Process, and Outcome Mutumba M, Musiime V, Tsai AC, Byaruhanga J, Kiweewa F, Bauermeister JA, Snow RC. J Assoc Nurses AIDS Care. 2015 Jul-Aug;26(4):472-84. doi: 10.1016/j.jana.2015.02.001. Epub 2015 Feb 12.
  11. Pubertal development in HIV-infected African children on first-line antiretroviral therapy. Szubert AJ, Musiime V, Bwakura-Dangarembizi M, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, Nathoo K, Prendergast AJ, Walker AS; ARROW Trial Team. AIDS. 2015 Mar 13;29(5):609-18. doi: 10.1097/QAD.0000000000000590.
  12. Psychosocial challenges and strategies for coping with HIV among adolescents in Uganda: a qualitative study. Mutumba M, Bauermeister JA, Musiime V, Byaruhanga J, Francis K, Snow RC, Tsai AC. AIDS Patient Care STDS. 2015 Feb;29(2):86-94. doi: 10.1089/apc.2014.0222. Epub 2015 Jan 21.
  13. Development of a psychosocial distress measure for Ugandan adolescents living with HIV. Mutumba M, Resnicow K, Bauermeister JA, Harper GW, Musiime V, Snow RC, Lepkowski JM. AIDS Behav. 2015 Feb;19(2):380-92. doi: 10.1007/s10461-014-0973-y.
  14. Opportunities for improving the efficiency of paediatric HIV treatment programmes. Revill PA, Walker S, Mabugu T, Nathoo KJ, Mugyenyi P, Kekitinwa A, Munderi P, Bwakura-Dangarembizi M, Musiime V, Bakeera-Kitaka S, Nahirya-Ntege P, Walker AS, Sculpher MJ, Gibb DM. AIDS. 2015 Jan 14;29(2):201-10. doi: 10.1097/QAD.0000000000000518.
  15. Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugyenyi P, Nahirya P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team. Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491.
  16. Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D. Longosz AF, Morrison CS, Chen PL, Brand HH, Arts E, Nankya I, Salata RA, Quinn TC, Eshleman SH, Laeyendecker O. AIDS Res Hum Retroviruses. 2015 Apr;31(4):421-7. doi: 10.1089/AID.2014.0081. Epub 2014 Nov 19.
  17. Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African Sagara I, Oduro AR, Mulenga M, Dieng Y, Ogutu B, Tiono AB, Mugyenyi P, Sie A, Wasunna M, Kain KC, Djimdé AA, Sarkar S, Chandra R, Robbins J1, Dunne MW. Malar J. 2014 Nov 25;13:458. doi: 10.1186/1475-2875-13-458
  18. The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models. Ford D, Robins JM, Petersen ML, Gibb DM, Gilks CF, Mugyenyi P, Grosskurth H, Hakim J, Katabira E, Babiker AG, Walker AS; DART Trial Team. Am J Epidemiol. 2015 Oct 1;182(7):633-43. doi: 10.1093/aje/kwv083. Epub 2015 Aug 26.
  19. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.
  20. Prevalence of latent rheumatic heart disease among HIV-infected children in Kampala, Uganda. Gleason B, Mirembe G, Namuyonga J, Okello E, Lwabi P, Lubega I, Lubega S, Musiime V, Kityo C, Salata RA, Longenecker CT. J Acquir Immune Defic Syndr. 2015 Sep 18.
  21. Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial. Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks CF, Goodall R, Spyer M, Kityo C, Pillay D, Gupta RK; DART Virology Group. PLoS One. 2015 Sep 18;10(9):e0137834. doi: 10.1371/journal.pone.0137834. eCollection
  22.  
  23. Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa. Sutherland KA, Goodall RL, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Thiltgen G, Gilks CF, Spyer M, Kityo C, Pillay D, Dunn D, Gupta RK. AIDS Res Hum Retroviruses. 2015 Oct;31(10):1032-7. doi: 10.1089/aid.2015.0138. Epub 2015 Aug 10.
  24.  
  25. Pretreatment HIV Drug Resistance Increases Regimen Switches in Sub-Saharan Africa. Boender TS, Hoenderboom BM, Sigaloff KC, Hamers RL, Wellington M, Shamu T, Siwale M, Labib Maksimos EE, Nankya I, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Ondoa P, Rinke de Wit TF. Clin Infect Dis. 2015 Aug 3. pii: civ656.
  26.  
  27. Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years. Musoke P, Szubert AJ, Musiime V, Nathoo K, Nahirya-Ntege P, Mutasa K, Williams DE, Prendergast AJ, Spyer M, Walker AS, Gibb DM; ARROW Trial Team. AIDS. 2015 Aug 24;29(13):1623-32.
  28.  
  29. Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals. Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN, McClure MO; SPARTAC Trial Investigators, Kellam P, Pybus OG. Philos Trans R Soc Lond B Biol Sci. 2015 Sep 5;370(1676). pii: 20140241. doi: 10.1098/rstb.2014.0241.
  30.  
  31. Structured observations reveal slow HIV-1 CTL escape. Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators. PLoS Genet. 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015
  32.  
  33. Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women. Lemonovich TL, Watkins RR, Morrison CS, Kwok C, Chipato T, Musoke R, Arts EJ, Nankya I, Salata RA. J Int Assoc Provid AIDS Care. 2015 Sep;14(5):415-22. doi: 10.1177/2325957413504827. Epub 2013 Oct 8.
  34.  
  35. Handheld echocardiography versus auscultation for detection of rheumatic heart disease. Godown J, Lu JC, Beaton A, Sable C, Mirembe G, Sanya R, Aliku T, Yu S, Lwabi P, Webb CL, Ensing GJ. Pediatrics. 2015 Apr;135(4):e939-44. doi: 10.1542/peds.2014-2774. Epub 2015 Mar 16.
  36.  
  37. The utility of handheld echocardiography for early rheumatic heart disease diagnosis: a field study. Beaton A, Lu JC, Aliku T, Dean P, Gaur L, Weinberg J, Godown J, Lwabi P, Mirembe G, Okello E, Reese A, Shrestha-Astudillo A, Bradley-Hewitt T, Scheel J, Webb C, McCarter R, Ensing G, Sable C. Eur Heart J Cardiovasc Imaging. 2015 May;16(5):475-82. doi: 10.1093/ehjci/jeu296. Epub 2015
  38.  
  39. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial Veronica Mulenga, Victor Musiime, Adeodata Kekitiinwa, Adrian D Cook, George Abongomera, Julia Kenny, Chisala Chabala, Grace Mirembe,Alice Asiimwe, Ellen Owen-Powell, David Burger, Helen McIlleron, Nigel Klein, Chifumbe Chintu, Margaret J Thomason, Cissy Kityo, A Sarah Walker, Diana M Gibb, on behalf of the CHAPAS-3 trial team. thelancet.com/infection Published online October 6, 2015 http://dx.doi.org/10.1016/S1473-3099(15)00319-9
  40.  
  41. Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda.Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips A, Katabira E, Musiime V, Gilks C, Chan A, Hakim J, Colebunders R, Kityo C, Gibb DM, Seeley J, Ford D; Lablite Project Team.BMC Health Serv Res. 2015 Nov 28;15(1):527. doi: 10.1186/s12913-015-1194-4.
  42.  
  43. Neurocognitive function at first-line failure and on second-line antiretroviral therapy in Africa: Analyses from the EARNEST Trial.Kambugu A, Thompson J, Hakim J, Tumukunde D, van Oosterhout JJ, Mwebaze R, Hoppe A, Abach J, Kwobah C, Arenas-Pinto A, Walker AS, Paton NI.J Acquir Immune Defic Syndr. 2015 Nov 16. [Epub ahead of print]
  44.  
  45. Cardiac Dysfunction Among Ugandan HIV-Infected Children on Antiretroviral Therapy.Namuyonga J, Lubega S, Musiime V, Lwabi P, Lubega I.Pediatr Infect Dis J. 2015 Nov 12. [Epub ahead of print]
  46.  
  47. Draft Genome Sequences of Mycobacterium bovis BZ 31150 and Mycobacterium bovis B2 7505, Pathogenic Bacteria Isolated from Archived Captive Animal Bronchial Washes and Human Sputum Samples in Uganda.Wanzala SI, Nakavuma J, Travis DA, Kia P, Ogwang S, Sreevatsan S.Genome Announc. 2015 Oct 8;3(5). pii: e01102-15. doi: 10.1128/genomeA.01102-15.PMID:26450718
  48.  
  49. A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, “the Nevirapine Repeat Pregnancy study".Kiweewa FM, Bakaki PM, McConnell MS, Musisi M, Namirembe C, Nakayiwa F, Kusasira F, Nakintu D, Mubiru MC, Musoke P, Fowler MG.BMC Public Health. 2015 Sep 29;15(1):988. doi: 10.1186/s12889-015-2345-6.PMID:26420040
  50. Using Exclusion-Based Sample Preparation (ESP) to Reduce Viral Load Assay Cost. Berry SM, Pezzi HM, Williams ED, Loeb JM, Guckenberger DJ, Lavanway AJ, Puchalski AA, Kityo CM, Mugyenyi PN, Graziano FM, Beebe DJ. PLoS One. 2015 Dec 2;10(12):e0143631. doi: 10.1371/journal.pone.0143631. eCollection 2015. PMID:26630135
List of all Publications